iAluRil is a medical device presented in a prefilled syringe. The solution within the syringe is instilled directly into the bladder to help rebuild the damaged bladder lining.
It contains three active ingredients:
  • HA Hyaluronic acid 800mg/50ml (1.6%)
  • CS Chondroitin sulphate 1g /50ml (2%)
  • CaCl Calcium chloride (0.87%)

What is iAluRil used for?

Effective treatment of:

  • Bladder Pain Syndrome / Interstitial Cystitis
  • Radiation Cystitis (irradiation of pelvic tumours)
  • Chemical Cystitis (BCG)

And relief and prevention of:

  • Recurrent Bacterial Cystitis (rUTIs)

What comes in the box?

  1. Prefilled syringe containing 50ml of iAluRil
  2. Plunger to be screwed onto the end of the syringe
  3. Luer-lock adapter for attaching to an intermittent catheter
  4. iAluadapter® to attach to the end of the syringe for catheter-free instillation of iAluRil
Learn more about the iAluadapter here

iAluRil active ingredients

Sodium Hyaluronate (HA)

Chondroitin Sulphate (CS)

These elements bind together with water molecules to create a waterproof protective lining to the inside of the bladder¹.

Calcium Chloride (CaCl)

The addition of calcium chloride is what makes iAluRil different.

Calcium chloride stabilises the iAluRil solution and provides superior adhesive and protective properties¹⁻³.

Restoring a healthy bladder

What makes iAluRil different?

Combination GAG therapy

As a healthy GAG layer is made of more than one component, it follows that an effective therapy will contain a combination. iAluRil is the only GAG therapy to contain both HA and CS; a combination which allows a more effective replenishment of the GAG layer.

The only 3 component GAG therapy

Not only is iAluRil the only combination GAG therapy, it is also the only one to contain 3 components. The addition of
calcium chloride (CaCl) provides:

Stability:
Calcium (Ca2+) ions help stabilise sodium hyaluronate (HA) and sodium chondroitin sulphate (CS) in the solution³⁻⁴

Persistence:

iAluRil is able to adhere to the bladder epithelium due to its mucoadhesive properties²

Functionality:
Calcium ions support movement of electrolytes, helping to maintain the protective effect of the GAG layer ¹’³

Viscosity:
iAluRil’s optimised viscosity profile supports ease of instillation⁵

Evidence-based and clinically proven

iAluRil has the most evidence of any GAG therapy, with the most clinical studies and
high quality data from a range of different types of trials.

  • 1st in class with level 1b data and over 70 publications⁶
  • The only GAG therapy with comparative data vs. multiple antibiotic prophylaxis regimens⁷⁻⁹
  • The only GAG therapy with multiple published, placebo controlled trials⁶’⁹

References

Hurst, Robert E et al. “Functional and structural characteristics of the glycosaminoglycans of the bladder luminal surface’’ The Journal of Urology vol. 138 (1987) 0022-5347/87/1382-0433

Stellavato, Antonietta et al. “Hyaluronic acid and chondroitin sulfate, alone or in combination, efficiently counteract induced bladder cell damage and inflammation.’’ ESSM Poster, Ljubljana 2019

Gribbon P, Heng BC, Hardingham TE. “The analysis of intermolecular interactions in concentrated hyaluronan solutions suggest no evidence for chain-chain association.’’ Biochem J. 2000 Aug 15;350 Pt 1:329-35.

Horkay, Ferenc et al. “Chondroitin Sulfate in Solution: Effects of Mono- and Divalent Salts.” Macromolecules vol. 45,6 (2012): 2882-2890. doi:10.1021/ma202693s

Zoppetti G, Puppini N, Pizzutti M. 2006 May 26; “Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis’’ EP2034956B1

Damiano R, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic Acid and chondroitin sulphate: a placebocontrolled randomised trial. Eur Urol. 2011
Apr; 59(4):645-51. Epub 2011 Jan 18

Gugliotta et al. Is intravesical instillation of hyaluronic acid and chondroitin sulphate useful in preventing recurrent bacterial cystitis? A multicentre case
control analysis. Taiwanese Journal of Obstetrics and Gynaecology 2015; 54:537-540

Torella M et al. intravesical therapy in recurrent cystitis: a multicentre experience. Journal of Infection and
Chemotherapy 2013; 10.1007/s10156-013-0609-6

De Vita D, Long-term efficacy of intravesical instillation of hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: 36 months’
follow-up. Clin.and Exp. Obstet. & Gynecol. – CEOG XLV n.2,2018

Always read the label.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148.

IAL1010244C2_DEC2023